---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-122952"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2026-11-05T11:04:15+00:00"
generated_at: "2026-11-05T11:11:11.451815+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics gets Nasdaq bid-price deficiency notice; Q3 net loss narrows to $4.1M

## Summary
- Nasdaq deficiency letter dated Nov. 3, 2026: CGTX closing bid below $1.00 for 30 consecutive business days; 180 days to May 3, 2027 to regain compliance.
- No immediate delisting; shares continue trading on Nasdaq Capital Market. Company may get a second 180-day period and could use a reverse stock split to cure.
- Q3 2026 net loss $4.1M, or $(0.04) per share, vs $4.9M, or $(0.06), in Q3 2025; R&D rose to $5.1M from $3.8M.
- Cash and restricted cash $31.5M at Sept. 30, 2026, plus $18.2M obligated NIA grant funds; runway estimated into Q4 2027.
- FDA aligned on Phase 3 endpoints for zervimesine (CT1812) in dementia with Lewy bodies; Phase 2 START topline expected in 2H 2027.

## SEC filing metadata
- accession: 0001104659-26-122952
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2026-11-05T11:04:15+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465926122952/0001104659-26-122952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465926122952/tm2629072d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-122952
- JSON: https://secwatch.observer/filing/0001104659-26-122952.json
- Plain text: https://secwatch.observer/filing/0001104659-26-122952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.